In 2013, Big Sellers in PGx Market Remain Herceptin, Gleevec with Newer Agents Poised to Take Over | GenomeWeb

In 2013, the top selling pharmacogenetically targeted drugs were well-known personalized medicine products, Herceptin and Gleevec.

Both of these drugs are slated to face generic competition soon, however, and when they do, drugmakers have newer agents in their pipelines to take their place. Meanwhile, across the PGx market, as new drugs are launched addressing smaller and smaller patient subsets, it raises the question whether any other personalized drugs will be able to match Herceptin or Gleevec's revenue success.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In PLOS this week: cell-free DNA from tumors is shorter than DNA from healthy cells, type 2 diabetes-related loci, and more.

Genetic analysis confirms that blood found on leaves collected near Marche-les-Dames some 80 years ago belongs to King Albert I of Belgium.

Researchers in the US begin to seek participants for the 1 million-person precision medicine cohort, the New York Times reports.

A new report indicates that women are underrepresented among US patent holders.